Jefferies Positive on Intra-Cellular Therapies (ITCI): 'We like the setup ahead of the second MDD readout in late-Q2'
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $105.00 price target on Intra-Cellular Therapies (NASDAQ: ITCI).The analyst comments "ITCI ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
